<p>Data are <i>n</i> (percent of regimen). Categories differentiate full DOT (here meaning entire course was taken in hospital) compared with various combinations of partial DOT when a child was discharged mid-course to receive the remainder of the course in the community, either with daily or alternate-day DOT of one of the day's doses and the remainder administered by the caretaker at home.</p>†<p>Courses in this row included in model in <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001739#pmed.1001739-t006" target="_blank">Table 6</a>.</p><p>Number of courses by dose regimen and administration regimen.</p
<p>P1: 1A vs. c-IMRT P2: 2A vs. c-IMRT P3: 2A vs.1A P4: 3A vs.2A P5: 3A vs. c-IMRT</p><p>Dosimetric ...
<p>(A) TRD rates among trials with different study periods. (B) TRD rates between arms with high and...
M indicate month(s); VKA vitamin K antagonists. *Note. If there is one symbol in the pattern categor...
<p>Data are ECP (95% CI). See <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal....
<p>*NA = not applicable</p><p>** Administered dose / planned dose according to the protocol per coho...
<p>Number of included doses (n) and error rates (%) stratified by day of the week, administration ro...
<p>Prescriptions for adult (age >18 yrs).</p><p>Metabolism, Metabolism & endocrinology; Gen Med, Gen...
Proportion of the study participants with respective understanding level of dosage regimen instructi...
<p>Percentages presented are row percentages for 6 and 12 mo use. Products with (1) a total number o...
*CTX = Average number of course treatments per prescription **Meds = Average number of medications p...
<p>Note: In each scenario, the first row of number in parentheses corresponds to the dose selection ...
<p>Proportion of time in therapeutic range (%) for patients on different vitamin K antagonists<sup><...
#<p> This refers to the number of patients switching treatment due to specific toxicity specified on...
<p>Bold text indicates roll-out of medicines’ monitoring and Profile administration 1 month before t...
<p>* Patients were enrolled on the Intermittent dosing schedule first, and then enrolled on the dail...
<p>P1: 1A vs. c-IMRT P2: 2A vs. c-IMRT P3: 2A vs.1A P4: 3A vs.2A P5: 3A vs. c-IMRT</p><p>Dosimetric ...
<p>(A) TRD rates among trials with different study periods. (B) TRD rates between arms with high and...
M indicate month(s); VKA vitamin K antagonists. *Note. If there is one symbol in the pattern categor...
<p>Data are ECP (95% CI). See <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal....
<p>*NA = not applicable</p><p>** Administered dose / planned dose according to the protocol per coho...
<p>Number of included doses (n) and error rates (%) stratified by day of the week, administration ro...
<p>Prescriptions for adult (age >18 yrs).</p><p>Metabolism, Metabolism & endocrinology; Gen Med, Gen...
Proportion of the study participants with respective understanding level of dosage regimen instructi...
<p>Percentages presented are row percentages for 6 and 12 mo use. Products with (1) a total number o...
*CTX = Average number of course treatments per prescription **Meds = Average number of medications p...
<p>Note: In each scenario, the first row of number in parentheses corresponds to the dose selection ...
<p>Proportion of time in therapeutic range (%) for patients on different vitamin K antagonists<sup><...
#<p> This refers to the number of patients switching treatment due to specific toxicity specified on...
<p>Bold text indicates roll-out of medicines’ monitoring and Profile administration 1 month before t...
<p>* Patients were enrolled on the Intermittent dosing schedule first, and then enrolled on the dail...
<p>P1: 1A vs. c-IMRT P2: 2A vs. c-IMRT P3: 2A vs.1A P4: 3A vs.2A P5: 3A vs. c-IMRT</p><p>Dosimetric ...
<p>(A) TRD rates among trials with different study periods. (B) TRD rates between arms with high and...
M indicate month(s); VKA vitamin K antagonists. *Note. If there is one symbol in the pattern categor...